Fabian Gerlinghaus, Alexander Seyf, and Knut Steffensen go behind the headlines and dive into the advanced therapy ecosystem.

Along with cooling trade-war concerns, a more upbeat outlook on the economy would likely spur deals. We’ve seen strategists ...

Salesforce Inc, PepsiCo Inc, FTSE 350 Aerospace & Defense, Skechers USA Inc. Read 's Market Analysis on Investing.com ...

Genmab A/S ADS has a trailing 12 month Price to Earnings (P/E) ratio of 12.7 while the S&P 500 average is 29.3 Its forward ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. | Following a ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

The most notable example of this trend is Germany's DAX index, which comprises the 40 largest publicly listed companies on the Frankfurt Stock Exchange. Since the end of the bear market in October ...

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies ...